Prostate cancer is the most prevalent type of cancer for U.S. men (about 192,280 new cases this year), and it is the second highest contributor to cancer death among men in the U.S. (27,360 will die of it this year). A major issue in prostate cancer detection and therapy is that we currently have no method to reliably distinguish aggressive prostate cancer from non-aggressive prostate cancer using available biomarkers. This leads to significant unnecessary suffering among prostate cancer patients and leads to massive unnecessary health care expenditures. We hypothesize that specific glycoproteins and glycan modifications of glycoproteins can be used to distinguish aggressive from non-aggressive prostate cancer in tissue and serum. We propose in four specific aims to develop novel glycoprotein biomarkers that can detect aggressive cancer in primary tissues and pre-surgical serum.
In Aim 1, we will analyze glycans and glycoproteins from metastatic, aggressive cancer, non-aggressive cancer, and normal prostate tissues to identify glycoproteins associated with aggressive prostate cancer.
In Aim 2, we will develop highly sensitive, specific, and high throughput MS based SRM assays for the candidate glycopeptides identified from Aim 1. We will optimize the SRM assays and determine their analytical performance, and construct an SRM database and make the assay available to the research community.
In Aim 3, we will use the developed SRM assays from Aim 2 to verify the glycoproteins for aggressive prostate cancer in additional prostate cancer tissues and validate these tissue glycoproteins using tissue microarrays.
In Aim 4, we will use the SRM assays to determine which of the verified glycopeptides in tissues can be detected in patient's sera, and therefore can be used as serum tests. Then, we will apply the SRM assays to the serum samples and develop validate multivariate models for detecting aggressive prostate cancer using serum tests. In addition, we will validate these markers and multivariate models using an independent testing set of prostate cancer serum. If successful, the identified and validated biomarkers will be tested by EDRN biomarker reference (BRL) and clinical validation (CVC) laboratories in retrospective and prospective studies. Biomarkers capable of distinguishing aggressive from nonaggressive prostate cancer would present men with non-aggressive prostate cancer from overtreatment, and could allow men with aggressive cancer to receive appropriate treatment earlier in the course of their diseases. SRM = selected reaction monitoring

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project--Cooperative Agreements (U01)
Project #
1U01CA152813-01
Application #
7983235
Study Section
Special Emphasis Panel (ZCA1-SRLB-C (M1))
Program Officer
Kagan, Jacob
Project Start
2010-09-01
Project End
2015-06-30
Budget Start
2010-09-01
Budget End
2011-06-30
Support Year
1
Fiscal Year
2010
Total Cost
$466,295
Indirect Cost
Name
Johns Hopkins University
Department
Pediatrics
Type
Schools of Medicine
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21218
Osmani, Lais; Askin, Frederic; Gabrielson, Edward et al. (2018) Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy. Semin Cancer Biol 52:103-109
Höti, Naseruddin; Yang, Shuang; Hu, Yingwei et al. (2018) Overexpression of ? (1,6) fucosyltransferase in the development of castration-resistant prostate cancer cells. Prostate Cancer Prostatic Dis 21:137-146
Yang, Shuang; Zhang, Lei; Thomas, Stefani et al. (2017) Modification of Sialic Acids on Solid Phase: Accurate Characterization of Protein Sialylation. Anal Chem 89:6330-6335
Shah, Punit; Yang, Weiming; Sun, Shisheng et al. (2017) Platelet glycoproteins associated with aspirin-treatment upon platelet activation. Proteomics 17:
Höti, Naseruddin; Shah, Punit; Hu, Yingwei et al. (2017) Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics 17:
Zhou, Jianliang; Yang, Weiming; Hu, Yingwei et al. (2017) Site-Specific Fucosylation Analysis Identifying Glycoproteins Associated with Aggressive Prostate Cancer Cell Lines Using Tandem Affinity Enrichments of Intact Glycopeptides Followed by Mass Spectrometry. Anal Chem 89:7623-7630
Yang, Shuang; Höti, Naseruddin; Yang, Weiming et al. (2017) Simultaneous analyses of N-linked and O-linked glycans of ovarian cancer cells using solid-phase chemoenzymatic method. Clin Proteomics 14:3
Liu, Yansheng; Gonzàlez-Porta, Mar; Santos, Sergio et al. (2017) Impact of Alternative Splicing on the Human Proteome. Cell Rep 20:1229-1241
Yang, Shuang; Hu, Yingwei; Sokoll, Lori et al. (2017) Simultaneous quantification of N- and O-glycans using a solid-phase method. Nat Protoc 12:1229-1244
Yang, Weiming; Shah, Punit; Hu, Yingwei et al. (2017) Comparison of Enrichment Methods for Intact N- and O-Linked Glycopeptides Using Strong Anion Exchange and Hydrophilic Interaction Liquid Chromatography. Anal Chem 89:11193-11197

Showing the most recent 10 out of 78 publications